levalbuterol inhalation

×

Overview

What is levalbuterol inhalation?

Levalbuterol Inhalation Solution, USP is a sterile, clear, colorless, preservative-free solution of the hydrochloride salt of levalbuterol, the (R)-enantiomer of the drug substance racemic albuterol. Levalbuterol HCl is a relatively selective beta-adrenergic receptor agonist [see Clinical Pharmacology ()]. The chemical name for levalbuterol HCl is (R)-α-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol hydrochloride, and its established chemical structure is as follows:

The molecular weight of levalbuterol HCl is 275.8, and its empirical formula is CHNO•HCl. It is a white to off-white, crystalline solid, with a melting point of approximately 187°C and solubility of approximately 180 mg/mL in water.

Levalbuterol HCl is the USAN modified name for (R)-albuterol HCl in the United States.

Levalbuterol Inhalation Solution, USP is supplied in unit-dose vials and requires no dilution before administration by nebulization. Each 3 mL unit-dose vial contains 0.31 mg (0.0103%) of Levalbuterol (as 0.36 mg of levalbuterol HCl) or 0.63 mg (0.021%) of levalbuterol (as 0.73 mg of levalbuterol HCl) or 1.25 mg (0.042%) of levalbuterol (as 1.44 mg of levalbuterol HCl), edetate disodium as a chelating agent, sodium chloride to adjust tonicity, and sulfuric acid to adjust the pH to 4.0 (3.3 to 4.5).

What does levalbuterol inhalation look like?

What are the available doses of levalbuterol inhalation?

Inhalation Solution (unit-dose vial for nebulization): 0.31 mg/3 mL, 0.63 mg/3 mL and 1.25 mg/3 mL. ()

What should I talk to my health care provider before I take levalbuterol inhalation?

How should I use levalbuterol inhalation?

Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Levalbuterol Inhalation Solution, USP is for oral inhalation only. Administer by nebulization using with a standard jet nebulizer (with a face mask or mouthpiece) connected to an air compressor. Do not exceed recommended dose.

Children 6-11 years old:

Adults and Adolescents ≥12 years old:

Patients 12 years of age and older with more severe asthma or patients who do not respond adequately to a dose of 0.63 mg of Levalbuterol Inhalation Solution, USP may benefit from a dosage of 1.25 mg three times a day.

Patients receiving the highest dose of Levalbuterol Inhalation Solution, USP should be monitored closely for adverse systemic effects, and the risks of such effects should be balanced against the potential for improved efficacy.

The use of Levalbuterol Inhalation Solution, USP can be continued as medically indicated to help control recurring bouts of bronchospasm. During this time, most patients gain optimal benefit from regular use of the inhalation solution.

If a previously effective dosage regimen fails to provide the usual response this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.

The drug compatibility (physical and chemical), efficacy, and safety of Levalbuterol Inhalation Solution, USP when mixed with other drugs in a nebulizer have not been established.

The safety and efficacy of Levalbuterol Inhalation Solution, USP have been established in clinical trials when administered using the PARI LC Jet™ and PARI LC Plus™ nebulizers, and the PARI MasterDura-Neb2000 and Dura-Neb3000 compressors. The safety and efficacy of Levalbuterol Inhalation Solution, USP when administered using other nebulizer systems have not been established.

What interacts with levalbuterol inhalation?

Sorry No Records found

What are the warnings of levalbuterol inhalation?

Sorry No Records found

What are the precautions of levalbuterol inhalation?

Sorry No Records found

What are the side effects of levalbuterol inhalation?

Sorry No records found

What should I look out for while using levalbuterol inhalation?

Levalbuterol Inhalation Solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [].

What might happen if I take too much levalbuterol inhalation?

The expected symptoms with overdosage are those of excessive beta-adrenergic receptor stimulation and/or occurrence or exaggeration of any of the symptoms listed under , e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min., arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia also may occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with the abuse of Levalbuterol Inhalation Solution. Treatment consists of discontinuation of Levalbuterol Inhalation Solution together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Levalbuterol Inhalation Solution.

How should I store and handle levalbuterol inhalation?

Store at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USALevalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.Levalbuterol Inhalation Solution, USP is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg,0.63 mg, 1.25 mg). Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf-carton containing 5 foil pouches, each containing 5 unit-dose LDPE vials.Levalbuterol Inhalation Solution, USP, 0.31 mg(strength in foil pouch label color green)NDC 43598-412-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 0.63 mg(strength in foil pouch label color yellow)NDC 43598-410-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Levalbuterol Inhalation Solution, USP, 1.25 mg(strength in foil pouch label color red)NDC 43598-409-25 : 5 foil pouches, each containing 5 unit-dose LDPE vials, total 25 vials per carton.Store Levalbuterol Inhalation Solution, USP in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Activation of beta-adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3′, 5′-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. Levalbuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Levalbuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. While it is recognized that beta-adrenergic receptors are the predominant receptors on bronchial smooth muscle, data indicate that there are beta-receptors in the human heart, 10% to 50% of which are beta-adrenergic receptors. The precise function of these receptors has not been established [see ]. However, all beta-adrenergic agonist drugs can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Non-Clinical Toxicology

Levalbuterol Inhalation Solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [].

Potassium-sparing diuretics, angiotensin converting enzyme inhibitors (see ).

The following serious adverse reactions are described below and elsewhere in the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: